Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Fair Value

Margin Of Safety %

Put/Call OI Ratio

0.3

Float Short​ %​

12.33

EPS 1 Diff

-2.25

EPS Year Diff

0.45

Ticker: PRTA




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-09-06PRTA20.350.380.025328
2024-09-09PRTA20.250.35999.995686
2024-09-10PRTA20.740.350.005656
2024-09-11PRTA20.960.34999.995696
2024-09-12PRTA20.70.350.065721
2024-09-13PRTA22.120.350.015679
2024-09-16PRTA21.860.340.495799
2024-09-17PRTA21.930.340.095937
2024-09-18PRTA21.50.341.035946
2024-09-19PRTA21.680.350.276165
2024-09-20PRTA21.610.350.006508
2024-09-23PRTA22.190.350.015062
2024-09-24PRTA22.070.330.015247
2024-09-25PRTA20.430.320.795338
2024-09-26PRTA20.130.350.005486
2024-09-27PRTA20.040.330.085691
2024-09-30PRTA16.720.310.956122
2024-10-01PRTA16.650.310.336631
2024-10-02PRTA16.690.300.056705
2024-10-03PRTA16.830.300.126709
2024-10-04PRTA16.860.300.216730
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-09-06PRTA20.33-405.3- -2.30
2024-09-09PRTA20.40-405.3- -2.30
2024-09-10PRTA20.76-405.3- -2.30
2024-09-11PRTA20.90-405.3- -2.30
2024-09-12PRTA20.70-405.3- -2.30
2024-09-13PRTA22.06-405.3- -2.30
2024-09-16PRTA21.85-405.3- -2.30
2024-09-17PRTA21.81-405.3- -2.30
2024-09-18PRTA21.48-405.3- -2.30
2024-09-19PRTA21.67-405.3- -2.30
2024-09-20PRTA21.61-405.3- -2.30
2024-09-23PRTA22.01-405.3- -2.30
2024-09-24PRTA22.01-405.3- -2.30
2024-09-25PRTA20.45-405.3- -2.30
2024-09-26PRTA20.14-405.3- -2.30
2024-09-27PRTA20.05-405.3- -2.30
2024-09-30PRTA16.71-405.3- -2.30
2024-10-01PRTA16.65-405.3- -2.30
2024-10-02PRTA16.68-405.3- -2.30
2024-10-03PRTA16.82-407.9- -2.31
2024-10-04PRTA16.86-407.9- -2.31
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-09-06PRTA0.00-4.1111.59
2024-09-09PRTA0.00-4.1111.59
2024-09-10PRTA0.00-4.1111.59
2024-09-11PRTA0.00-4.1111.59
2024-09-12PRTA0.00-4.1112.05
2024-09-13PRTA0.00-4.1112.05
2024-09-16PRTA0.00-4.1112.05
2024-09-17PRTA0.00-4.1112.05
2024-09-18PRTA0.00-4.1112.05
2024-09-19PRTA0.00-4.1112.05
2024-09-20PRTA0.00-4.1112.05
2024-09-23PRTA0.00-4.1112.05
2024-09-24PRTA0.00-4.1112.05
2024-09-25PRTA0.00-4.1112.33
2024-09-26PRTA0.00-4.1112.33
2024-09-27PRTA0.00-4.1112.33
2024-09-30PRTA0.00-4.1112.33
2024-10-01PRTA0.00-4.1112.33
2024-10-02PRTA0.00-4.1112.33
2024-10-03PRTA0.00-4.1112.33
2024-10-04PRTA0.00-4.1112.33
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

1.22

Avg. EPS Est. Current Quarter

-1.16

Avg. EPS Est. Next Quarter

-1.03

Insider Transactions

Institutional Transactions

-4.11

Beta

0.16

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

9

Fair Value (Academic)

Quality Score

29

Growth Score

35

Sentiment Score

15

Actual DrawDown %

78.9

Max Drawdown 5-Year %

-78.9

Target Price

55.88

P/E

Forward P/E

PEG

P/S

4.17

P/B

1.56

P/Free Cash Flow

EPS

-1.01

Average EPS Est. Cur. Y​

-2.31

EPS Next Y. (Est.)

-4.28

Target Price Estimates Raised

Target Price Estimates Lowered

1

Profit Margin

-23.44

Relative Volume

1.61

Return on Equity vs Sector %

-30.4

Return on Equity vs Industry %

-51.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

Prothena Corporation plc
Sector: Healthcare
Industry: Biotechnology
Employees: 173
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
stock quote shares PRTA -Prothena Corporation plc Stock Price stock today
news today PRTA -Prothena Corporation plc stock forecast ,stock prediction 2023 2024 2025
marketwatch PRTA -Prothena Corporation plc yahoo finance google finance
stock history PRTA -Prothena Corporation plc invest stock market
stock prices PRTA premarket after hours
ticker PRTA fair value insiders trading